Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Bridge Science Begins China JV

publication date: Jun 11, 2009

Bio-Bridge Science, a vaccine development company, has signed a joint venture agreement with JR Scientific Inc., a California maker of classical and custom cell culture medium and sera products. The JV will produce cell culture medium in a Beijing facility. The new JV will be capitalized with 10 million RMB ($1.5 million). Bio-Bridge Science will contribute 5.1 million RMB for a 51% share of the JV; JRS will provide technology in return for a 15% stake; and other investors will add the remaining capital. More details...

Stock Symbol: (OTCBB: BGES)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital